KFA115 / Novartis - LARVOL DELTA

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2026 ➔ Sep 2027 | Trial primary completion date: Feb 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Anal Carcinoma • Breast Cancer • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Microsatellite Instability • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymus Cancer • Triple Negative Breast Cancer • MSI

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Combination therapy • Metastases • Trial completion date • Trial primary completion date • Anal Carcinoma • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Microsatellite Instability • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymus Cancer • MSI

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Anal Carcinoma • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Microsatellite Instability • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymus Cancer • MSI

A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers (clinicaltrials.gov) - P1 | N=220 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

Combination therapy • New P1 trial • Anal Carcinoma • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Cutaneous Melanoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Microsatellite Instability • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thymic Carcinoma • Thymus Cancer • MSI